16 recruiting, 2 active not recruiting, 2 completed, 2 not yet recruiting. 22 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Recruiting 16, Active not recruiting 2, Completed 2, Not yet recruiting 2 |
| Phase 1 | 5 | Recruiting 5 |
Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
| A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" Elranatamab - Phase 2, Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 34 | 2026-03-31 | 2026-09-18 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
| ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) Lenalidomide, Dexamethasone, Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | University of Miami | 104 | 2025-09-16 | 2026-09-21 |
| Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy Letermovir - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 2 | Recruiting | Seoul National University Hospital | 40 | 2025-09-11 | 2025-12-03 |
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Nantes University Hospital | 176 | 2025-07-09 | 2026-11-13 |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma Elranatamab - Myeloma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 39 | 2025-05-27 | 2025-12-03 |
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | Thomas Lund | 20 | 2025-01-29 | 2026-02-10 |
| Elranatamab in Relapsed/Refractory Multiple Myeloma Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | University of California, San Diego | 33 | 2024-12-18 | 2026-02-20 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-17 | 2026-08-10 |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma Elranatamab - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 50 | 2024-05-14 | 2026-09-02 |
| Elranatamab in R/R Multiple Myeloma Elranatamab - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 32 | 2024-03-08 | 2026-08-31 |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma AZD0305, Elranatamab, Pomalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-05 | 2026-10-30 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
Showing 20 of 22. Sign in to see all of them.
Multiple Myeloma (18) · Recurrence (3) · Immunoglobulin Light-chain Amyloidosis (2) · Neoplasms, Plasma Cell (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1)
M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · Pfizer (2) · SCRI Development Innovations, LLC (2) · AstraZeneca (1) · Case Comprehensive Cancer Center (1) · Celgene (1) · CellCentric Ltd. (1) · Dana-Farber Cancer Institute (1) · European Myeloma Network B.V. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Nantes University Hospital (1) · PETHEMA Foundation (1) · Seoul National University Hospital (1) · Thomas Lund (1)
United States (15) · France (4) · Spain (4) · United Kingdom (4) · China (3) · Canada (2) · Germany (2) · Japan (2) · Norway (2) · South Korea (2) · Australia (1) · Brazil (1) · Denmark (1) · Greece (1) · Italy (1)
Noopur Raje, MD (2) · Ah-Reum Jeong (1) · Albert Oriol, PhD (1) · Carl O Landgren, MD (1) · Christine Ye, MD (1) · Enrique Ocio, PhD (1) · Giada Bianchi (1) · Hans Lee, MD (1) · Henning Schade, MD (1) · Melissa Alsina, MD (1) · Qaiser Bashir, MD (1) · Sandra Mazzoni, DO (1) · Thomas Lund, MD (1)
PMID 40000533, PMID 40826257, PMID 42287565
2023 (1), 2025 (1)